Hopkinson Craig C. (CIK 1730048) reported 39 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-01). Recent activity: Buy ALKS (5,000 shares), Sell ALKS (9,000 shares), Buy ALKS (104 shares), Buy ALKS (4,896 shares), Sell ALKS (9,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 5,000 | $122,950 |
| 2026-09-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 9,000 | $422,874 |
| 2026-08-03 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 104 | $2,011 |
| 2026-08-03 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 4,896 | $120,393 |
| 2026-08-03 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 9,000 | $437,220 |
| 2026-07-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 5,000 | $96,700 |
| 2026-07-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 8,300 | $427,129 |
| 2026-07-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 700 | $36,492 |
| 2026-06-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 5,000 | $96,700 |
| 2026-06-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 9,000 | $375,030 |
| 2026-05-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 5,000 | $96,700 |
| 2026-05-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 9,000 | $300,600 |
| 2026-04-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 9,000 | $319,590 |
| 2026-04-01 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 5,000 | $96,700 |
| 2026-03-04 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 5,000 | $96,700 |
| 2026-03-04 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 9,000 | $267,480 |
| 2026-02-27 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 6,866 | $0 |
| 2026-02-27 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 3,049 | $93,696 |
| 2026-02-25 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 7,689 | $0 |
| 2026-02-25 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 3,414 | $109,897 |
| 2026-02-20 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 8,897 | $0 |
| 2026-02-20 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 3,504 | $112,198 |
| 2026-02-20 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 7,673 | $0 |
| 2026-02-20 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Sell | 3,407 | $109,024 |
| 2026-02-06 | Alkermes plc. (ALKS) | EVP R&D, Chief Medical Officer | Buy | 25,352 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-01